Johnson & Johnson shares have risen sharply, but valuation debate persists after a three-year rally

Johnson & Johnson’s stock has climbed about 82% over the past three years, a move that has left investors weighing whether the shares are now fairly valued or could still offer upside. In a market note published by Yahoo Finance, the performance was framed as a strong run, with the article citing an 81.9% gain over the three-year period leading up to the Aug. 29, 2026 publication date.

The core question in the analysis is not whether the stock rose, but what that rise implies for valuation going forward. The post says an intrinsic value estimate points toward potential upside, implying that the company’s longer-term cash-generating ability may be undervalued relative to the current share price.

That view is presented as at odds with market pricing, which the article describes as leaning in a different direction. Rather than aligning the market’s valuation multiples with the intrinsic value work, the note characterizes the multiple-based picture as less supportive of additional upside, effectively setting up a split between “model value” and “market value.”

The practical implication is that the shares may be responding to expectations that are already partly priced in, even if a valuation framework based on fundamentals would calculate a higher value than today’s market. In other words, the rally could be driven by optimism about future earnings power, while valuation multiples could be indicating less room for further gains unless results improve.

Johnson & Johnson operates in the healthcare sector and is known for a broad portfolio spanning pharmaceuticals and consumer health products, a structure that typically shapes how analysts think about earnings stability and long-term cash flows. For investors, that business mix can matter because intrinsic valuation methods often translate those cash-flow characteristics into a present-day value estimate, while market multiples can reflect investor sentiment and the perceived risk or growth profile embedded in the sector.

The article’s framing also suggests that the debate may be sensitive to the assumptions behind any “intrinsic value” calculation, because the conclusion hinges on how future profitability, discount rates, and other inputs are modeled. At the same time, multiple-based approaches can shift quickly with changes in interest-rate expectations and broader market risk appetite, which may explain why the article sees market and model indicates pointing in different directions.

What the market note does not disclose in the excerpt is the specific methodology behind the intrinsic estimate, such as the exact assumptions used or the sensitivity of the conclusion to those inputs. It also does not provide, in the available text, the exact market multiples it refers to or how those multiples compare with any historical ranges, leaving readers without the full numerical detail needed to judge the size of the gap between the two valuation views.

Looking ahead, investors likely will focus on whether upcoming company performance and guidance can reconcile the two perspectives. If results and cash flows come in stronger than what the market has priced, the intrinsic-value argument could gain traction. If performance merely meets expectations, market multiples may dominate, limiting upside even after a strong three-year run. The next step for investors is to watch for updates that can narrow the valuation disagreement, particularly any disclosures that affect earnings durability and longer-term cash generation.